Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(2), P. 406 - 406
Published: Jan. 10, 2025
Objectives:
Vaccination
against
SARS-CoV-2
has
been
vital
in
alleviating
the
spread
of
recent
pandemic.
We
aimed
to
estimate
frequency
and
type
adverse
events
related
vaccine
patients
with
lupus
nephritis
(LN),
assess
its
impact,
if
any,
on
risk
subsequent
reactivation
nephritis.
Methods:
This
was
a
retrospective,
multicenter
study
which
included
biopsy-proven
LN,
who
had
received
at
least
one
dose.
Patients
ended
up
end-stage
kidney
disease
(ESKD)
prior
vaccination
or
were
diagnosed
LN
after
excluded.
Adverse
events,
systemic
local,
COVID-19
outcomes
(full
recovery,
death,
long
COVID-19),
outcome
(remission,
refractory
disease,
relapse,
ESKD
death),
demographics,
laboratory
measurements,
immunosuppressive
regimens
recorded.
Results:
Sixty-seven
included.
The
median
age
33
(20-46)
years.
Induction
therapy
for
administered
92.5%
74.6%
maintenance
therapy.
Of
these,
94.02%
remission
vaccination.
BNT162b2
mRNA
97.01%
cases,
mild
symptoms
28.35%
(myalgias
17.91%,
headache
13.43%,
arthralgias
fever
10.44%)
local
effects
35.82%
(pain
25.37%,
swelling
13.43%).
Overall,
among
upon
vaccination,
two
(3.17%)
experienced
relapse
within
5.75
(±0.25)
months,
while
75%
those
active
achieved
21
(±2)
months.
Conclusions:
appears
safe
without
serious
occurring,
there
is
no
significant
impact
clinical
course
disease.
Deleted Journal,
Journal Year:
2025,
Volume and Issue:
22(1)
Published: Jan. 2, 2025
Abstract
COVID-19
vaccines
effectively
reduce
morbidity
and
mortality
but
are
associated
with
Events
Supposedly
Attributable
to
Vaccination
or
Immunization
(ESAVI).
This
cross-sectional
study
examined
the
incidence
characteristics
of
ESAVI
in
Brazil
during
2021,
using
data
from
e-SUS
Notifica
Vacivida.
Among
109,424
reports,
rates
were
30.82
83.08
symptoms
per
100,000
doses.
Most
reports
involved
women
(70.83%),
individuals
aged
30–39,
residents
southern
region.
Common
included
headache,
fever,
myalgia.
AstraZeneca
accounted
for
56.79%
cases.
Non-severe
cases
predominated
(95.03%),
78.7%
classified
as
“product-related
according
literature.”
Mortality
was
rare
(0.03%),
a
significant
association
identified
between
DNA
deaths
(χ
2
=
4.333;
p
0.037;
OR
2.673;
95%
CI
1.020–7.007).
Regional
disparities
evident,
higher
incidences
South
Southeast.
Underreporting
non-severe
remains
challenge.
Logistic
regression
showed
lower
odds
severe
among
adults
Black/Brown
individuals,
while
Pfizer
initial
doses
linked
odds.
These
results
highlight
safety
emphasizing
need
strengthened
post-vaccination
surveillance
address
regional
disparities,
health
inequities,
vaccine
hesitancy.
Vaccines,
Journal Year:
2025,
Volume and Issue:
13(3), P. 284 - 284
Published: March 7, 2025
Background:
Patients
with
hematological
malignancies,
including
multiple
myeloma
(MM)
and
chronic
lymphocytic
leukemia
(CLL),
are
at
an
increased
risk
of
severe
infections
due
to
both
disease-
therapy-related
immunosuppression.
This
cross-sectional
study
evaluated
awareness
infection
risks
vaccination
uptake
among
150
adults
various
malignancies
from
major
Polish
centers.
Methods:
All
participants
completed
a
30-item
questionnaire
capturing
demographic
data,
treatment
history,
frequency,
attitude.
Statistical
analyses
utilized
Chi-square
Fisher’s
exact
tests,
p
<
0.05
considered
statistically
significant.
Results:
Respondents
had
median
age
57
years
(range,
30–79),
65.3%
were
female.
MM
was
the
most
common
diagnosis
(64.7%),
followed
by
CLL
(4.0%)
other
(31.3%).
Nearly
all
(99.3%)
acknowledged
their
susceptibility
infections.
Frequent
(≥2
in
past
6
months)
significantly
associated
transfusion
dependency
(p
=
0.0001)
history
hematopoietic
stem
cell
transplantation
(HSCT,
0.009).
Although
69.3%
expressed
willingness
be
vaccinated,
23.3%
declined
COVID-19
insufficient
cancer-specific
safety
data.
Higher
education
urban
residence
correlated
greater
acceptance
vaccines
0.05).
Conclusions:
Our
findings
underscore
critical
need
for
targeted
educational
strategies
robust
guidelines
this
immunocompromised
population.
Enhanced
patient
timely
implementation
tailored
regimens
could
reduce
infection-related
morbidity
improve
tolerability
cancer
treatments.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(2), P. 406 - 406
Published: Jan. 10, 2025
Objectives:
Vaccination
against
SARS-CoV-2
has
been
vital
in
alleviating
the
spread
of
recent
pandemic.
We
aimed
to
estimate
frequency
and
type
adverse
events
related
vaccine
patients
with
lupus
nephritis
(LN),
assess
its
impact,
if
any,
on
risk
subsequent
reactivation
nephritis.
Methods:
This
was
a
retrospective,
multicenter
study
which
included
biopsy-proven
LN,
who
had
received
at
least
one
dose.
Patients
ended
up
end-stage
kidney
disease
(ESKD)
prior
vaccination
or
were
diagnosed
LN
after
excluded.
Adverse
events,
systemic
local,
COVID-19
outcomes
(full
recovery,
death,
long
COVID-19),
outcome
(remission,
refractory
disease,
relapse,
ESKD
death),
demographics,
laboratory
measurements,
immunosuppressive
regimens
recorded.
Results:
Sixty-seven
included.
The
median
age
33
(20-46)
years.
Induction
therapy
for
administered
92.5%
74.6%
maintenance
therapy.
Of
these,
94.02%
remission
vaccination.
BNT162b2
mRNA
97.01%
cases,
mild
symptoms
28.35%
(myalgias
17.91%,
headache
13.43%,
arthralgias
fever
10.44%)
local
effects
35.82%
(pain
25.37%,
swelling
13.43%).
Overall,
among
upon
vaccination,
two
(3.17%)
experienced
relapse
within
5.75
(±0.25)
months,
while
75%
those
active
achieved
21
(±2)
months.
Conclusions:
appears
safe
without
serious
occurring,
there
is
no
significant
impact
clinical
course
disease.
